Overview

Study of IRNEA (Irinotecan, Etoposide, Cytarabine) for Refractory or Relapsed Acute Leukemia in Children and Adolescents

Status:
Unknown status

Trial end date:
2013-12-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the maximum tolerable dose of irinotecan in combination with etoposide, cytarabine for refractory or relapsed acute leukemia in pediatric patient.

Phase:

Phase 1

Details

Lead Sponsor:

Seoul National University Hospital

Treatments:

Camptothecin
Cytarabine
Etoposide
Etoposide phosphate
Irinotecan